HER2 status in unusual histological variants of gastric adenocarcinomas

Journal of Clinical Pathology

Volumn 65, Issue 3, 2012, Pages 237-241

  Giuffrè, Giuseppe ^a   Ieni, Antonio ^a   Barresi, Valeria ^a   Caruso, Rosario Alberto ^a   Tuccari, Giovanni ^a  

^a Section of Pathological Anatomy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84857361082     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200345     Document Type: Article

References (36)

1. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68. (Pubitemid 32619394)
2. Latif Z, Watters AD, Bartlett JM, et al. Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 2002;89:5-9. (Pubitemid 34117755)
3. Leyland-Jones B. Trastuzumab therapy for the metastatic patient: does the primary match? Ann Oncol 2002;13:993-4.
4. Oxley JD, Winkler MH, Gillatt DA, et al. Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 2002;55:118-20. (Pubitemid 34123912)
5. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39:724-7. (Pubitemid 36930120)
6. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti- HER2 therapy? Eur J Cancer 2004;40:56-63. (Pubitemid 37542318)
7. Hansel DE, Ashfaq R, Rahman A, et al. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening and treatment. Am J Clin Pathol 2005;123:28-35. (Pubitemid 40066169)
8. Ugocsai K, Mándoky L, Tiszlavicz L, et al. Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res 2005;25:3061-6. (Pubitemid 41044701)
9. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
11. Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8. (Pubitemid 40309309)
12. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009;101:1306-7.
13. Moelans CB, Milne AN, Morsink FH, et al. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol 2011;34:89-95.
14. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9.
15. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
16. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011;18:53-9.
17. Caruso RA, Tuccari G. A proposal of additional immunohistochemical markers for hepatoid carcinomas of the foregut. Pathology 1996;28:288.
18. Caruso RA, Basile F, Fedele F, et al. Gastric hepatoid adenocarcinoma with autophagy-related necrosis-like tumor cell death: report of a case. Ultrastruct Pathol 2006;30:301-17.
19. Liu X, Cheng Y, Sheng W, et al. Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol 2010;34:1465-71.
20. Takubo K, Honma N, Sawabe M, et al. Oncocytic adenocarcinoma of the stomach. Am J Surg Pathol 2002;26:458-65.
21. Caruso RA, Napoli P, Nania A. Mitochondrion-rich differentiated adenocarcinomas of the stomach: clinicopathological, immunohistochemical and electron microscopy study of nine cases. Virchows Arch 2010;456:499-505.
22. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC, 2010.
23. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-49.
24. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-77.
25. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.
26. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-42.
27. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
28. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
29. Varis A, Zaika A, Puolakkainen P, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 2004;109:548-53. (Pubitemid 38339645)
30. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9. (Pubitemid 44315804)
31. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.
32. Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol 2007;38:857-63. (Pubitemid 46726508)
33. Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, et al. Hepatoid adenocarcinoma of the stomach e a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol 2009;6:13.
34. Inagawa S, Shimazaki J, Hori M, et al. Hepatoid adenocarcinoma of the stomach. Gastric Cancer 2001;4:43-52. (Pubitemid 32625935)
35. Bartlett JM, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2011;64:649-53.
36. Yoon DH, Kang Y-K. Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. Clin Investig 2011;1:87-95.